Tirzepatide in District 2: What Weight-Loss Trials Reveal About Changes in Body Composition
Research Snapshot
Tirzepatide clinical trials demonstrate substantial reductions in body weight, but scale weight alone cannot show which tissues account for that change. A dual-energy X-ray absorptiometry (DXA) substudy of SURMOUNT-1, published in 2025, provides direct evidence that reductions in fat mass account for most of the weight lost, while lean mass also decreases.
Among 160 participants with evaluable DXA scans at baseline and week 72, the pooled tirzepatide group experienced mean reductions of 21.3% in body weight, 33.9% in fat mass, and 10.9% in lean mass. Approximately 74% of the weight lost was attributed to fat mass and 26% to lean mass. Visceral fat mass and waist circumference also decreased substantially.
A 2026 retrospective real-world study of 35 adults reported that fat mass accounted for approximately 85.7% of total weight loss. However, it used bioelectrical impedance analysis (BIA), included a small cohort, and lacked a randomized control group. Its findings complement the controlled-trial evidence but should not be treated as directly interchangeable with DXA results.
Bottom line: Tirzepatide-associated weight loss is predominantly fat loss in the available body-composition studies, but it is not exclusively fat loss. The amount and clinical significance of lean-tissue change require interpretation alongside the measurement method, physical function, and broader clinical outcomes.
Key Takeaways
- Weight loss and fat loss are not synonymous. Body weight includes fat, lean tissue, bone mineral, and body water.
- SURMOUNT-1 provides controlled-trial evidence. Its DXA substudy found that approximately three-quarters of the weight lost with tirzepatide came from fat mass.
- Lean mass also declined. The substudy reported a mean 10.9% reduction in lean mass, but this should not be described as an equivalent percentage loss of skeletal muscle.
- Visceral fat and waist circumference decreased. These are distinct outcomes from total body weight and total fat mass.
- Measurement methods matter. DXA and BIA estimate body composition differently, which limits direct comparisons between studies.
- Real-world evidence remains preliminary. The 2026 BIA study offers useful context but cannot establish that its results are representative of all tirzepatide users.
- Composition does not establish function. A change in lean mass alone cannot determine whether strength, mobility, or physical performance has improved or deteriorated.
1. Why Body Composition Is More Informative Than Scale Weight Alone
Body weight is a combined measure of several components. These include fat mass, lean soft tissue, bone mineral, and body water. Two people who lose the same amount of weight may experience different changes in these components.
Fat mass represents the body’s stored fat. Lean mass is a broader category that includes non-fat tissues such as muscle, organs, connective tissue, and water, depending on the measurement method and terminology. Skeletal muscle is only one component of lean tissue. Visceral adipose tissue (VAT), meanwhile, refers to fat within the abdominal cavity around internal organs.
These measures answer different scientific questions:
- Total body weight: How much did the person weigh at the measurement point?
- Fat mass: How much of the measured body mass is attributed to fat?
- Lean mass: How much is attributed to non-fat tissue under the method used?
- Visceral fat: What change occurred in a specific abdominal fat depot?
- Physical function: Did strength, mobility, or performance change alongside body composition?
A decrease in total weight does not automatically establish a proportional decrease in body fat. Likewise, a measured decrease in lean mass does not by itself prove a clinically important loss of muscle function. Body-composition studies are valuable because they help distinguish these outcomes rather than treating them as interchangeable.
2. How Tirzepatide Produces Weight Reduction
Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. These incretin pathways participate in glucose regulation and appetite-related signaling.
Its pharmacological effects include glucose-dependent stimulation of insulin secretion, modulation of glucagon secretion, and changes in appetite and food intake. Tirzepatide also delays gastric emptying, particularly early in treatment, although this effect diminishes over time.
By reducing energy intake, tirzepatide can create conditions in which the body draws on stored energy. During sustained weight reduction, the body generally loses a combination of fat and lean tissue rather than fat alone. The relative contribution of each component varies among individuals and depends on baseline characteristics, the magnitude of weight loss, nutrition, activity, health status, and other factors.
The mechanism does not selectively target adipose tissue to the exclusion of lean tissue. Therefore, claims that tirzepatide produces exclusively fat-based weight loss are not supported by the available DXA evidence.
3. SURMOUNT-1: The Main Weight-Loss Trial
Jastreboff and colleagues published SURMOUNT-1 in The New England Journal of Medicine in 2022. This phase 3, double-blind, randomized, placebo-controlled trial enrolled 2,539 adults with obesity, or overweight with at least one weight-related complication. Participants with diabetes were excluded from this particular trial.
Participants received tirzepatide at one of three weekly dose levels or placebo for 72 weeks, including a dose-escalation period. All participants were offered lifestyle intervention. The primary endpoints were percentage change in body weight and the proportion of participants achieving at least 5% weight reduction.
Under the treatment-regimen estimand, which assessed outcomes regardless of treatment discontinuation, mean body-weight changes at week 72 were −15.0% with 5 mg, −19.5% with 10 mg, and −20.9% with 15 mg, compared with −3.1% with placebo.
These findings establish the scale of the treatment effect in the parent trial. However, the main trial’s weight outcomes do not show precisely how much fat mass or lean mass changed in every participant. That question was examined in a smaller DXA substudy published in 2025.
4. The SURMOUNT-1 DXA Substudy: Design and Population
Look and colleagues evaluated body-composition changes in a substudy of SURMOUNT-1. Participants underwent whole-body DXA scans at baseline and week 72. DXA uses low-dose X-rays to estimate body composition, including fat mass and lean mass.
Of the 2,539 participants enrolled in SURMOUNT-1, 255 entered the DXA substudy and 160 had evaluable baseline and follow-up scans for the reported efficacy analysis. This included 124 participants receiving pooled tirzepatide doses and 36 receiving placebo.
The participants with evaluable scans were 73% female, with a mean baseline body weight of 102.5 kg and a mean BMI of 38.0 kg/m². The pooled tirzepatide analysis combined participants assigned to the 5 mg, 10 mg, and 15 mg groups.
The primary objective was to compare percentage change in fat mass between the pooled tirzepatide group and placebo. The investigators also evaluated lean mass, visceral fat mass, waist circumference, and the proportion of total weight loss attributed to fat and lean mass.
The DXA substudy provides more detail than scale weight alone, but its 160 participants with evaluable scans represent only a subset of the larger trial. Its findings are strong evidence for the measured changes in that subset, not a direct measurement of body composition for every SURMOUNT-1 participant.
5. What Changed at Week 72?
The DXA substudy found statistically significant reductions in body weight, fat mass, and lean mass with tirzepatide compared with placebo. The pooled tirzepatide group also showed greater reductions in visceral fat mass and waist circumference.
Fat mass declined more sharply than lean mass in relative terms. Yet the lean-mass reduction is an important part of the results and should not be omitted when describing the overall body-composition response.
| Measure at week 72 | Pooled tirzepatide | Placebo | Interpretation |
|---|---|---|---|
| Body weight | −21.3% | −5.3% | Greater overall weight reduction in the tirzepatide group |
| Fat mass | −33.9%; approximately −15.9 kg | −8.2%; approximately −3.6 kg | Fat mass accounted for most of the observed weight reduction |
| Lean mass | −10.9%; approximately −5.6 kg | −2.6%; approximately −1.2 kg | Lean mass also declined; this is not equivalent to a direct measurement of muscle function |
| Visceral fat mass | −40.1% | −7.3% | Estimated visceral fat decreased substantially in the tirzepatide group |
| Waist circumference | −18.1 cm | −3.4 cm | Abdominal circumference declined alongside weight and fat mass |
| Share of weight loss | Approximately 74% fat mass and 26% lean mass | Approximately 75% fat mass and 25% lean mass | The proportions were similar despite the larger absolute and percentage weight reduction with tirzepatide |
Primary source: Look et al., 2025, Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study.
Reporting note: The authors subsequently published a correction to the labeling of the y-axis in Figure 4. The corrected axis describes change from baseline in kilograms, not percentage change. The numerical results summarized above follow the article’s reported text and tables rather than the incorrect original figure-axis label.
6. What the 75:25 Ratio Does—and Does Not—Mean
The commonly cited ratio of approximately 75% fat mass and 25% lean mass describes the average composition of weight lost in the DXA substudy. It does not mean every participant lost exactly 75% of their weight as fat and 25% as lean tissue.
For illustration, if a hypothetical person lost 20 kg and the same ratio applied, approximately 15 kg would be attributed to fat mass and 5 kg to lean mass. This is a mathematical example, not a prediction of an individual response to tirzepatide.
The ratio also should not be interpreted as a unique property of tirzepatide. The placebo group had a similar average distribution of weight loss between fat and lean mass, although the magnitude of total weight loss was much smaller. In other words, tirzepatide produced substantially greater weight reduction, but the relative proportions attributed to fat and lean mass were similar in this substudy.
The study reported that these proportions remained relatively consistent across most post hoc subgroup analyses by age, sex, and degree of weight reduction. Some exceptions were observed. Because subgroup analyses are less definitive than primary prespecified endpoints, they should not be used to make strong predictions about an individual person’s body composition.
7. Fat Mass, Visceral Fat, Lean Mass, and Skeletal Muscle Are Different Measures
These terms are related but not interchangeable. Understanding the distinction is essential for reading clinical studies accurately.
| Measure | What it represents | What it cannot establish alone |
|---|---|---|
| Fat mass | Estimated total body fat | Whether all fat depots changed equally or whether long-term health outcomes improved |
| Visceral fat | Fat within the abdominal cavity around internal organs | A direct reduction in cardiovascular events or mortality |
| Lean mass | Estimated non-fat tissue, including more than skeletal muscle | The exact amount of muscle lost or whether strength has changed |
| Skeletal muscle mass | Estimated skeletal muscle tissue, depending on the measurement method | Muscle quality, strength, mobility, or functional performance by itself |
| Body water | Water within and outside cells | A direct measure of fat loss or skeletal muscle tissue loss |
In the SURMOUNT-1 substudy, visceral fat was estimated using DXA-derived measurements rather than direct CT or MRI imaging. DXA is useful for body-composition research, but the method used to estimate a specific fat depot matters when interpreting the result.
8. What the 2026 Real-World Study Adds
Corso and colleagues published a retrospective real-world study in Frontiers in Endocrinology on July 8, 2026. The study examined 35 adults receiving tirzepatide in a clinical obesity-management program that included individualized diet and exercise counseling. Body composition was estimated with an InBody 770 multifrequency BIA device at baseline and follow-up visits.
The study reported mean reductions of 27.8% in body weight, 54.2% in fat mass, 7.3% in fat-free mass, and 8.3% in estimated skeletal muscle mass. Fat mass accounted for approximately 85.7% of total weight loss in this cohort. Total body water also declined.
These results provide additional information about body-composition changes in routine care, but they are not directly comparable with the SURMOUNT-1 DXA substudy. The two studies differ in design, sample size, clinical setting, and measurement method.
- Study design: SURMOUNT-1 was randomized and placebo-controlled. The 2026 study retrospectively analyzed clinical records without a randomized control group.
- Sample size: The real-world analysis included 35 participants, making its estimates more sensitive to individual variation.
- Measurement method: SURMOUNT-1 used DXA, while the real-world study used BIA. BIA estimates body composition through electrical impedance and can be influenced by hydration and device-specific algorithms.
- Clinical context: Participants in the real-world study received specialist care and lifestyle counseling. The study therefore reflects a combined clinical setting, not an isolated medication effect.
- Percentage interpretation: The 85.7% estimate should not be interpreted as proof that tirzepatide generally produces a higher fat-loss proportion than the approximately 74% reported in the DXA substudy.
A higher estimated percentage of weight loss from fat does not automatically mean a treatment is more effective at preserving lean tissue. Before comparing studies, examine the sample size, population, follow-up, measurement technology, hydration sensitivity, and whether the study had a control group.
9. Why Lean-Mass Changes Deserve Attention
Lean tissue contributes to movement, physical function, and several aspects of metabolic health. Some decline in lean mass commonly occurs during weight reduction, including with lifestyle-based approaches. The relevant question is whether the amount lost is clinically meaningful and whether physical function is maintained.
The 10.9% reduction in DXA-derived lean mass in the SURMOUNT-1 substudy should not be described as a 10.9% reduction in skeletal muscle. DXA-derived lean mass includes tissues other than muscle, and hydration changes can also influence body-composition estimates.
The 2026 real-world study reported an 8.3% decline in estimated skeletal muscle mass, but that result was generated by BIA and does not directly measure muscle strength or physical performance. Neither study establishes that every participant experienced a harmful decline in muscle function.
Useful endpoints for future research include strength, mobility, physical performance, nutritional status, and the durability of body-composition changes over time. These measures help researchers distinguish changes in tissue estimates from changes that matter to daily function and health.
For general background on peptide-related research and evidence interpretation, explore the Vietnam Peptides Knowledge Hub and the Peptide Research FAQ.
10. How Researchers Should Interpret Body-Composition Measurements
Body-composition studies are most informative when the measurement method, study design, and limitations are considered together.
- DXA: Uses low-dose X-rays to estimate fat mass, lean mass, and bone mineral content. It is widely used in clinical research but does not directly measure muscle strength.
- BIA: Estimates body composition from electrical impedance. Hydration status, recent food or fluid intake, exercise, and device-specific algorithms can affect the estimates.
- CT and MRI: Can provide more direct anatomical information about specific fat depots, including visceral fat, but their outputs are not identical to whole-body DXA or BIA measures.
- Scale weight and waist circumference: Are accessible measures of body change, but neither can independently determine how much fat or lean tissue has changed.
- Functional assessments: Strength tests and physical-performance measures help determine whether changes in body composition correspond to changes in function.
For longitudinal research, the use of a consistent measurement method and standardized measurement conditions is important. Researchers should also account for baseline body composition, missing data, sample size, follow-up duration, and whether outcomes were prespecified or exploratory.
Results from a randomized clinical trial, a small retrospective cohort, and a device-based body-composition analysis answer different questions. They can complement each other, but they should not be treated as equally strong evidence for every claim.
11. Clinical Context and Evidence Limitations
Tirzepatide is a prescription medicine used in approved formulations for specified indications. In the United States, approved tirzepatide products include formulations indicated for type 2 diabetes management and chronic weight management in eligible patients, depending on the product label. Approved indications and regulatory status vary by jurisdiction and formulation.
The clinical evidence reviewed here applies to the formulations and conditions studied. It does not establish that every product sold under the name tirzepatide has equivalent identity, purity, potency, manufacturing quality, regulatory status, or clinical performance.
The official prescribing information for tirzepatide products includes important warnings and precautions, including gastrointestinal adverse reactions, acute pancreatitis, gallbladder disease, volume depletion-related kidney injury, and other risks. Specific indications, contraindications, and warnings differ by product label. Clinical decisions should be based on the applicable official prescribing information and assessment by a qualified healthcare professional.
Body-composition changes also should not be overinterpreted. A decrease in fat mass or visceral fat is not, by itself, proof of a reduction in every obesity-related complication or in mortality. Similarly, a measured decrease in lean mass does not automatically establish harm. Clinical interpretation requires consideration of the full benefit-risk profile and relevant patient outcomes.
12. Statistics and Evidence at a Glance
| Evidence source | Population and method | Key findings | Main limitation |
|---|---|---|---|
| SURMOUNT-1, 2022 | 2,539 randomized participants; 72 weeks | Mean weight change: −15.0%, −19.5%, and −20.9% in the 5 mg, 10 mg, and 15 mg groups; −3.1% with placebo | Parent-trial weight outcomes do not directly quantify body composition for every participant |
| SURMOUNT-1 DXA substudy, 2025 | 160 participants with evaluable scans; DXA at baseline and week 72 | Tirzepatide: weight −21.3%, fat mass −33.9%, lean mass −10.9%; about 74% of weight loss was attributed to fat mass | Small subset of the parent trial; pooled tirzepatide doses |
| Real-world study, 2026 | 35 adults; retrospective analysis using BIA | Weight −27.8%, fat mass −54.2%, fat-free mass −7.3%, estimated skeletal muscle mass −8.3%; approximately 85.7% of weight loss attributed to fat mass | Small cohort, no randomized control group, and a different measurement method |
Sources: SURMOUNT-1, NEJM, 2022; Look et al., 2025; Corso et al., 2026.
Frequently Asked Questions
The SURMOUNT-1 DXA substudy found reductions in both body weight and fat mass. Fat mass declined more sharply in percentage terms than lean mass, indicating that fat loss was the main contributor to the overall reduction in weight.
In the 2025 DXA substudy, approximately 74% of weight lost in the pooled tirzepatide group was attributed to fat mass and 26% to lean mass. These are group-level averages, not a guaranteed ratio for an individual.
No. Lean mass includes more than skeletal muscle, and DXA does not directly measure muscle strength or function. A reduction in lean mass should not be interpreted as an equivalent percentage reduction in muscle.
The 2026 study included 35 participants and used BIA in a retrospective clinical setting. The SURMOUNT-1 substudy used DXA and included 160 participants with evaluable scans. Differences in sample size, study design, population, and measurement method limit direct comparison between the reported percentages.
Fat mass estimates fat throughout the body. Visceral fat is a specific depot within the abdominal cavity around internal organs. A change in visceral fat does not necessarily mean that every fat depot changes by the same proportion.
Not necessarily. Some lean-mass reduction commonly occurs during weight loss. Its clinical significance depends on the amount lost, baseline health and body composition, and whether strength or physical function is affected. Body-composition estimates alone cannot answer all these questions.
No. Visceral fat is a relevant body-composition measure, but a change in that measure is not itself proof of a reduction in heart attacks, strokes, or mortality. Such conclusions require direct evidence from appropriate clinical-outcome studies.
DXA uses low-dose X-rays to estimate fat mass, lean mass, and bone mineral content. BIA estimates body composition from electrical impedance and can be affected by hydration and other measurement conditions. Their outputs should not automatically be treated as interchangeable.
No. The parent trial enrolled 2,539 participants, while the DXA efficacy analysis included 160 participants with evaluable baseline and follow-up scans. This smaller sample is an important limitation when generalizing the body-composition findings.
The available studies do not show that lean tissue is fully preserved. The DXA substudy reported a mean reduction in lean mass, and the real-world study reported a reduction in estimated skeletal muscle mass. More direct evidence on strength, mobility, and long-term physical function would help clarify the clinical significance.
No. Clinical evidence applies to the specific formulations and conditions studied. A product name or commercial description does not establish equivalent identity, purity, potency, manufacturing quality, regulatory status, or clinical performance.
Related Research Resources
Tirzepatide 20mg — Research Product Listing
This listing is relevant to readers researching tirzepatide and incretin-related compounds. A product listing is not evidence of regulatory approval, clinical efficacy, or pharmaceutical equivalence to an approved prescription formulation. Product information should be interpreted separately from clinical-trial findings.
Explore more educational material in the Vietnam Peptides Knowledge Hub, review the Peptide Research FAQ, or browse the research product directory.
Related Resource: Fat-Loss Research Plan
For a broader educational overview of fat-loss research and the interpretation of evidence across peptide-related topics, see the Fat-Loss Peptide Plan. This resource does not replace professional medical assessment or provide a personalized treatment recommendation.
Scientific References
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025;27(5):2720–2729. https://doi.org/10.1111/dom.16275
- Look M, Dunn JP, Kushner RF, et al. Correction to “Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.” Diabetes, Obesity and Metabolism. 2025;27(11):6823. https://doi.org/10.1111/dom.70050
- Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038
- Corso H, Graybeal AJ, Hoelscher E, Roberson S, Curran B, Johnson C, Johnson KE. Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity. Frontiers in Endocrinology. 2026;17:1834580. https://doi.org/10.3389/fendo.2026.1834580
- U.S. National Library of Medicine. Zepbound (tirzepatide) prescribing information. DailyMed. Official drug-label search
- U.S. National Library of Medicine. Mounjaro (tirzepatide) prescribing information. DailyMed. Official drug-label search
- National Institute of Diabetes and Digestive and Kidney Diseases. Prescription medications to treat overweight and obesity. NIDDK resource
Conclusion
Clinical trials show that tirzepatide can produce substantial reductions in body weight and fat mass. In the SURMOUNT-1 DXA substudy, approximately 74% of the weight lost was attributed to fat mass, while approximately 26% was attributed to lean mass. Visceral fat mass and waist circumference also declined, demonstrating that the observed changes extended beyond scale weight alone.
The 2026 real-world study adds a useful but preliminary perspective. Its higher estimated proportion of weight loss from fat should not be treated as a direct contradiction of the DXA results because the studies used different methods and designs.
The most defensible conclusion is that tirzepatide-associated weight loss is predominantly fat loss in the available body-composition studies, but it is not exclusively fat loss. Lean tissue, measurement uncertainty, physical function, and clinical safety remain important parts of the overall assessment. Future studies combining body-composition measurements with strength, mobility, and longer-term health outcomes will help clarify the clinical significance of these changes.